World Pathology: Constipation - Pipeline Review, H2 2011

• Publication date: October 2011

This report provides information on the therapeutic development for Constipation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Constipation. '' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press rel...

This report provides information on the therapeutic development for Constipation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Constipation. '' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of the Research

- A snapshot of the global therapeutic scenario for Constipation.
- A review of the Constipation products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Constipation pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Identify and understand important and diverse types of therapeutics under development for Constipation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Constipation pipeline depth and focus of Constipation therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Global Pathology Industry

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global March kets Direct Report Coverage 9
Constipation Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Constipation 11
Constipation Therapeutics under Development by Firms 13
Constipation Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Constipation Therapeutics - Products under Development by Firms 20
Constipation Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in Constipation Therapeutics Development 23
Abbott Laboratories 23
AstraZeneca PLC 23
Alkermes, Inc. 24
Dong-A Pharmaceutical Co., Ltd. 24
Norgine Limited 25
Ono Pharmaceutical Co., Ltd. 25
Progenics Pharmaceuticals, Inc. 26
Shire Plc 26
AlbireoPharma 27
Callisto Pharmaceuticals, Inc. 27
Cosmo Pharmaceuticals S.p.A 28
Adolor Corp. 28
ARYx Therapeutics 29
Theravance, Inc. 29
Sucampo Pharmaceuticals, Inc. 30
Ironwood Pharmaceuticals, Inc. 30
Giaconda Limited 31
KYORIN Pharmaceutical Co., Ltd. 31
Braintree Laboratories, Inc. 32
S.L.A. Pharma AG 32
Ardelyx, Inc. 33
MicroDose Therapeutx, Inc. 33
Beech Tree Labs, Inc. 34
SK Bio-Pharmaceuticals 34
Constipation - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
NKTR 118 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ATI-7505 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ADL7445 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Linaclotide - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Linaclotide - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Amitiza - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ALKS 37 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
M0012 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
MDT-006 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
TD-5108 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
SP-304 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Subcutaneous Methylnaltrexone - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Oral Methylnaltrexone - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Ibaconda - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Sodium Chenodeoxycholate - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
YKP-GI - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ONO-3849 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Pyridostigmine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Methylnaltrexone - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
TD-1211 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
A3309 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Naloxone - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ADL5945 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Neostigmine + Glycopyrrolate - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
CB-01-16 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Itopride - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Relistor - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Naloxone hydrochloride - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Methylnaltrexone - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
KRP-110 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Laxative Program - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Drug for Chronic Constipation - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
DA-6886 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
BLI-801 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
TD-8954 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
RDX5791 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
PF05 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Constipation Therapeutics – Drug Profile Updates 83
Constipation Therapeutics - Discontinued Products 91
Constipation - Featured News 92
October 03, 2011: Alkermes Initiates Phase IIb Clinical Study Of ALKS 37 For Treatment Of Opioid-Induced Constipation 92
August 10, 2011: Adolor Announces Positive Results From Phase II Program In Opioid Induced Constipation 92
August 09, 2011: Ironwood And Forest Announce Submission Of New Drug Application For Linaclotide To FDA 93
June 28, 2011: Progenics Submits RELISTOR Supplemental NDA For Treatment Of Opioid-Induced Constipation In Patients With Chronic, Non-Cancer Pain 94
June 06, 2011: Adolor Completes Enrollment In Phase II OIC Program 94
May 20, 2011: Progenics Announces Results Of Methylnaltrexone Phase III Safety Study In Chronic, Non-Malignant Pain Patients 95
May 10, 2011: o Clinic Researchers Find New Treatment For Constipation 96
May 09, 2011: Alkermes Presents Phase II Data Of ALKS 37 In Late-Breaking Oral Session At Digestive Disease Week Meeting 96
May 09, 2011: Sucampo And Abbott Report Phase III Clinical Trial Data Of Lubiprostone In Japanese Patients With Chronic Idiopathic Constipation At DDW 2011 97
May 04, 2011: Ironwood And Forest To Present Linaclotide Results From Phase III Trials In Patients With Irritable Bowel Syndrome With Constipation 99
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 102
Contact Us 102
Disclaimer 102

List of Tables

Number of Products Under Development for Constipation, H2 2011 11
Products under Development for Constipation – Comparative Analysis, H2 2011 12
Number of Products under Development by Firms, H2 2011 14
Number of Products under Investigation by Universities/Institutes, H2 2011 15
Comparative Analysis by Late Stage Development, H2 2011 16
Comparative Analysis by Mid Clinical Stage Development, H2 2011 17
Comparative Analysis by Early Clinical Stage Development, H2 2011 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011 19
Products under Development by Firms, H2 2011 20
Products under Development by Firms, H2 2011 21
Products under Investigation by Universities/Institutes, H2 2011 22
Abbott Laboratories, H2 2011 23
AstraZeneca PLC, H2 2011 23
Alkermes, Inc., H2 2011 24
Dong-A Pharmaceutical Co., Ltd., H2 2011 24
Norgine Limited, H2 2011 25
Ono Pharmaceutical Co., Ltd., H2 2011 25
Progenics Pharmaceuticals, Inc., H2 2011 26
Shire Plc, H2 2011 26
AlbireoPharma, H2 2011 27
Callisto Pharmaceuticals, Inc., H2 2011 27
Cosmo Pharmaceuticals S.p.A, H2 2011 28
Adolor Corp., H2 2011 28
ARYx Therapeutics, H2 2011 29
Theravance, Inc., H2 2011 29
Sucampo Pharmaceuticals, Inc., H2 2011 30
Ironwood Pharmaceuticals, Inc., H2 2011 30
Giaconda Limited, H2 2011 31
KYORIN Pharmaceutical Co., Ltd., H2 2011 31
Braintree Laboratories, Inc., H2 2011 32
S.L.A. Pharma AG, H2 2011 32
Ardelyx, Inc., H2 2011 33
MicroDose Therapeutx, Inc., H2 2011 33
Beech Tree Labs, Inc., H2 2011 34
SK Bio-Pharmaceuticals, H2 2011 34
Assessment by Monotherapy Products, H2 2011 35
Assessment by Combination Products 36
Assessment by Stage and Route of Administration, H2 2011 38
Assessment by Molecule Type, H2 2011 40
Constipation Therapeutics – Drug Profile Updates 83
Discontinued Products 91

List of Figures

Number of Products under Development for Constipation, H2 2011 11
Products under Development for Constipation – Comparative Analysis, H2 2011 12
Products under Development by Firms, H2 2011 13
Products under Investigation by Universities/Institutes, H2 2011 15
Late Stage Products, H2 2011 16
Mid Clinical Stage Products, H2 2011 17
Early Clinical Stage Products, H2 2011 18
Discovery and Pre-Clinical Stage Products, H2 2011 19
Assessment by Monotherapy Products, H2 2011 35
Assessment by Combination Products, H2 2011 36
Assessment by Route of Administration, H2 2011 37
Assessment by Stage and Route of Administration, H2 2011 38
Assessment by Molecule Type, H2 2011 39
Assessment by Stage and Molecule Type, H2 2011 40